Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
120,781,538
-
Total 13F shares
-
46,927,893
-
Share change
-
+6,781,648
-
Total reported value
-
$626,702,945
-
Put/Call ratio
-
79%
-
Price per share
-
$13.35
-
Number of holders
-
90
-
Value change
-
+$87,202,617
-
Number of buys
-
48
-
Number of sells
-
45
Institutional Holders of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) as of Q3 2017
As of 30 Sep 2017,
Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) was held by
90 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,927,893 shares.
The largest 10 holders included
FMR LLC, Temasek Holdings (Private) Ltd, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., Kohlberg Kravis Roberts & Co. L.P., VANGUARD GROUP INC, STATE STREET CORP, JPMORGAN CHASE & CO, UBS ASSET MANAGEMENT AMERICAS INC, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
90
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.